A Phase 2 Study of PF -04449913 for the Treatment of Acute Myeloid 
Leukemia Patients with High Risk of Post -Allogeneic Stem Cell 
Transplantation Relapse  
SPONSOR  /
 Coordinating 
Center  Univ er
sity of Colorado 
Cancer Center  
PARTI
CIPATING CENTER The Ohio S
tate University  
COMIRB 
# 12-1558
Vers
ion #  7 / Oc
tober 1 5, 2019  
CONFIDENTIAL  
The information contained in this document is regarded as confidential and, except to 
the extent necessary to obtain informed consent, may not be disclosed to another party unless law or regulations require such disclosure.  Persons to whom the information is disclosed must be informed that the information is confidential and may not be fur ther 
disclosed by them.  NCT#01841333 
 Confidential    
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 ii  
PRINCIPAL INVESTIGATOR SIGNATURE PAGE  
  
Principal Investigator:  
    
 Signature of Invest igator   Date  
 Printed Name of Investigator    
 By my signature, I agree to personally supervise the conduct of this study 
and to ensure its conduct in compliance with the protocol, informed consent, IRB procedures , the Declaration of Helsinki, ICH Good Clinical 
Practices guidelines, and the applicable parts of the United States Code of Federal Regulations or local regulations governing the conduct of clinical studies.
 
 
          
 Confidential    
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 iii STUDY PERSONNEL  
 
Sponsor :  University of Colorado Cancer Center  
1665 Aurora Court  
Aurora, CO 80045  
 
Study Locations:  University of Colorado Cancer Center , 
Aurora, CO  
 
The Ohio State University,  
Columbus, OH 
Investigator s:  Daniel A. Pollyea, MD , MS 
University of Colorado Cancer Center  
Mail Stop F754 , Room 4328  
1665 Aurora Court  
Aurora, CO 80045  
Phone: 720- 848-8084  
 
Jonathan Gutman, MD  
University of Colorado Cancer Center   
1665 Aurora Court  
Aurora, CO 80045  
Phone: 720- 848-0220  
 Sumithira Vasu, MBBS Ohio State University  
Division of Hematology  
B310 Starling Loving Hall  
320 W 10th Avenue  
Phone: 614- 293-8197  
Fax: 614- 293-7526  
Email: sumithira.vasu@osumc.edu  
 
  
 Confidential    
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 iv Contents  
1 PROTOCOL SYNOPSIS  .......................................................................................................... 1 
2 SCHEDULE OF STUDY ASSESSMENTS*  ............................................................................. 2 
3 INTRODUCTION  .................................................................................................................... 4 
3.1 Background and Rationale  ............................................................................................... 4 
3.2 PF-04449913 .................................................................................................................... 6 
4 STUDY OBJECTIVES  ............................................................................................................ 11 
4.1 Primary Objective .......................................................................................................... 11 
4.2 Secondary Objectives  ..................................................................................................... 11 
5 INVESTIGATIONAL PLAN  ................................................................................................... 12 
5.1 Overal l Study Design  ..................................................................................................... 12 
5.1.1  Dosing Schema  ...................................................................................................... 12 
5.1.2  Continuation and Interruptions  .............................................................................. 12 
5.2 Study Endpoints  ............................................................................................................. 12 
5.2.1  Primary Endpoint  ................................................................................................... 12 
5.2.2  Secondary Endpoints  ............................................................................................. 13 
5.3 Selection of Study Population and Enrollment Procedures  ........................................... 13 
5.3.1  Inclusion Criteria  ................................................................................................... 13 
5.3.2  Exclusion Criteria  .................................................................................................. 14 
5.3.3  Lifestyle  Guidelines  ............................................................................................... 15 
5.4 Duration of Study  ........................................................................................................... 16 
5.5 Drug Administration  ...................................................................................................... 16 
5.5.1  Premedication  ........................................................................................................ 16 
5.5.2  PF-04449913 .......................................................................................................... 16 
5.6 Assuring Pat ient Compliance  ......................................................................................... 17 
5.7 Laboratory Criteria for Initiation of Treatment Cycles  .................................................. 17 
5.8 St
udy Treatment Schedule  ............................................................................................. 17 
5.9 Concomitant Therapy  ..................................................................................................... 18 
5.9.1  Permitted Concomitant Therapy  ............................................................................ 18 
5.9.2  Prohibited Concomitant Therapy  ........................................................................... 18 
5.9.3  Table 1: Representative prohibited medications based on metabolic isoenzyme 
class.  ............................................................................................................... 19 
5.10  Safety Plan  ..................................................................................................................... 20 
5.10.1  Stopping Rules  ....................................................................................................... 20 
5.10.1.1  Individual Patients’ Stopping Rules ............................................................... 20 
5.10.1.2  Study Stopping Rules ..................................................................................... 21 
5.10.2  Dosing Delays and Modifications  .......................................................................... 22 
5.10.2.1  Missed Doses  ................................................................................................. 22 
5.10.2.2  Dose Delays and De- escalation  ..................................................................... 22 
5.10.3  Data and Safety Monitoring ................................................................................... 25 
5.11  Study
 Completion and Termination  ............................................................................... 26 
5.12  Study Activities and Assessments.................................................................................. 27 
5.12.1  Schedule of Activities  ............................................................................................ 27 
5.12.2  Screening Period  .................................................................................................... 27 
5.12.3  Treatment Schedule  ............................................................................................... 27 
5.12.4  Follow Up  .............................................................................................................. 28 
5.12.5  Study Assessments  ................................................................................................. 28 
5.12.5.1  Vital Signs and ECOG Performance Status  ................................................... 28 
5.12.5.2  Physical Examination  .................................................................................... 28 
5.12.5.3  Adverse Events  .............................................................................................. 28 
 Confidential    
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 v 5.12.5.4  Laboratory Assessments  ................................................................................ 29 
5.12.5.5  EKGs and QTc Calculation  ........................................................................... 29 
5.12.5.6  Minimal Residual Disease (MRD) ................................................................. 30 
5.12.5.7  Disease Assessments and Response Criteria  ................................................. 30 
5.12.5.8  Correlative Assessments  ................................................................................ 30 
5.13  Definitions and Reporting Procedures for Adverse Events  ........................................... 31 
5.13.1  Definitions of Adverse Events  ............................................................................... 31 
5.13.1.1  Adverse Event  ................................................................................................ 31 
5.13.1.2  Serious Adverse Event (SAE)  ........................................................................ 32 
5.13.1.3  Pregnancies  .................................................................................................... 32 
5.13.2  Relat ionship of the Adverse Event to Treatment  ................................................... 33 
5.13.3  Procedures for Recording Adverse Events  ............................................................ 34 
5.13.3.1  Information to be Collected  ........................................................................... 34 
5.13.3.2  Recording Serious Adverse Events  ................................................................ 34 
5.13.4  Investigator Reporting Responsibilities  ................................................................. 34 
5.13.4.1  Investigational New Drug Annual Reports  .................................................... 35 
5.13.4.2  Format for Adverse Event Reporting  ............................................................. 35 
5.13.4.3  Reporting to the IRB  ...................................................................................... 35 
5.13.4.4  Reporting to Pfizer  ......................................................................................... 35 
5.13.4.5  Non-serious Adverse Event Reporting  .......................................................... 35 
5.13.4.6  SAE Reporting  ............................................................................................... 36 
5.14  St
atistical Methods and Sample Size Determination  ..................................................... 37 
5.15  Protocol Deviations  ........................................................................................................ 37 
6 ADMINISTRATIVE REQUIREMENTS  .................................................................................. 37 
6.1 Data and Safety Monitoring Plan  ................................................................................... 37 
6.2 Ethics  ............................................................................................................................. 37 
6.2.1  Institutional Review Board  .................................................................................... 37  
6.2.2  Patie
nt Information and Consent ............................................................................ 38 
6.3 Record of Administration  .............................................................................................. 39 
6.4 Confidentiality  ............................................................................................................... 39 
6.5 Study Auditing  ............................................................................................................... 40 
7 REFERENCES ....................................................................................................................... 41 
8 APPENDIX A - ECOG Performance Status Scale  ................................................................. 44 
9 APPENDIX B - Pfizer Safety Reporting Policy  ..................................................................... 45 
 
 
 Confidential    
      
    
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 1 1 PROTOCOL  SYNOPSIS  
PROTOCOL TITLE:   A Phase 2 Study of PF -04449913 For the Treatment of Acute Myeloid Leukemia  
Patients with High Risk of Post -Allogeneic Stem Cell Transplantation Relapse  
 
INDICATION:  Post allogeneic stem cell transplantation for acute myeloid leukemia patients with high 
risk of relapse  
STUDY PHASE:  2 
BACKGROUND AND RATIONALE:   Disease relapse is the most common cause of death after 
allogeneic stem cell transplantation for acute myeloid leukemia.  Patients at high risk for relapse may 
benefit from a novel, biologically rational therapeutic intervention to prevent this outcome.   PF -
04449913 is a small molecule inhibitor of the hedgehog (Hh) pathway that inhibits the protein 
Smoothened ( SMO ).  Aberrant Hh signaling may contribute to the survival and expansion of the 
leukemia stem cell, and inhibiting the Hh pathway can eliminate these cells.  Therefore, targeting Hh may be a logical intervention in the post -transplantation setting for those with high risk of relapse.  We 
propose a phase 2 study of PF -04449913 in patients with acute myeloid leukemia who have received 
an allogeneic  stem cell transplantation and are at high risk of relapse.     
STUDY OBJECTIVES:  
Primary:    
• Determine whether PF -04449913 can prevent relapse in high risk acute myeloid leukemia 
patients who receive an allogeneic stem cell transplantation  
Secondary:    
• Determine the toxicity profile of PF -04449913 in this population  
• Determine the impact of this intervention on overall survival (OS)  
STUDY DESIGN:  
This is an open label, phase 2 study employing PF -04449913 in acute myeloid leukemia patients who 
received an allogeneic  stem cell transplantation and are at high risk of relapse. Patients will receive 
consecutive 28- day cycles of PF -04449913 at 100 mg/day , beginning on post -transplantation day 28-
50, after their routine post -transplant bone marrow biopsy. Treatment  will continue for up to one year or  
until they experience toxicity or disease relapse. 50 patients will be required for a 9 0% power to detect 
a 20% difference in one-year relapse fr ee survival.  
STUDY ENDPOINTS  
Primary:  
• One year relapse- free survival  
Secondary:  
• Remission  duration  
• Incidence and severity of adverse events  
• OS (one year)  
STUDY DURATION:  5-7 years  TOTAL SAMPLE SIZE:  50 
 Confidential    
          
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 2 2 SCHEDULE OF STUDY ASSESSMENTS*  
 PF-
04449913  Hx/PE  Hema tology  Chemistry  Screening  
Labs  & 
Procedures  12-Lead 
EKG  MRD  BM 
Bx 
Screening †   X X X X X   
 
Cycle 1  Days 1-28 X        
Day 1  X¶ X¶ X¶  X   
Day 15   X X X  X   
Day 2 8‡  X X X     
Cycles  2 - 12 Days 1-28 X        
Day 1‡  X X X  X†*   
Initiation of New Azole 
Antifungal Medication        X¶*   
Post -transplant day 80 
+/- 10 days         X X 
Post -transplant day 
175 +/ - 15        X X 
Post -transplant day 
365 +/ - 30        X X 
 
DEFINITIONS:  
Hx/PE:  Complete or interim medical history, including ECOG performance status, adverse event monitoring and concomitant medications review; 
complete or focused physical examination. Drug compliance assessment will occur with each cycle’s day 1, beginning with cycle 2.  
Hematology: Complete blood count (includes hemoglobin, hematocrit, platelet count and total white blood cell count with differential)  
Chemistry:  Complete metabolic profile, including Na, K, calcium, CO2, BUN, creatinine, glucose, magnesium, phosphorous, protein, albumin, AST, ALT, 
alkaline phosphatase and total bilirubin  
Screening labs & procedures:  Prothrombin time (PT) and/or international normalized ration (INR), partial thromboplastin time (PTT); serum/urine 
pregnancy test for women of childbearing potential only must be performed within 72 hours of treatment initiation.  
12-lead EKG: To be performed with QTc interval calculated by Fridericia’s correction factor  if indicated.  
MRD: Minimal residual disease, as detected by multidimensional flow cytometry  (see Section 5.12.5.6)   
BM Bx:  Unilateral core and aspirate samples, to be sent for morphological assessment, cytogenetics, flow cytometry and molecular tes ting 
 
 Confidential    
          
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 3 FOOTNOTES  
*Variations of ±5 days of scheduled visits are permitted; unscheduled visits can occur at any time during the study.  The date of the unscheduled visit and 
any data generated must be recorded on the appropriate case report form, and source documents for these visits must also be m aintained.  
†Includes review of exclusion/inclusion criteria and informed consent.  
¶If screening and day 1 are ≤ 7 days apart, the Hx/PE, CMP and CBC performed at enrollment do not need to be repeated on day 1.  
‡Day 28 visit and labs may be same as day 1 visit and labs of the subsequent cycle 
***Perf orm 1- 4 hours after first dose (at Cmax)  
†* Perform 1- 4 hours after first dose (at Cmax)  for cycle 2, day 1 only; not necessary to routinely  repeat on day 1 of each cycle unless clinically indicated  
¶*Perform 2- 5 days after initiation of new azole antifungal medication
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 4 3 INTRODUCTION  
Hematopoietic stem cell transplantation (HSCT) is the only therapy with 
curative potential for high risk patients with acute myeloid leukemia (AML)  
2,3 However, disease relapse remains the main cause of treatment failure 
and death after HSCT,4 suggesting that even highly ablative therapies and 
the generation of immunological graft versus leukemia responses are very often unable to target the leukemia stem cell population and achieve the requisite cure.  At relapse, salvage maneuvers such as sec ondary 
transplantations or donor lymphocyte infusions are highly toxic and seldom effective,
5-7 highlighting the need for tolerable therapies in this population.  
 
Predicting imminent relapse in the post -transplant setting is becoming 
increasingly sophisticated.  In post-transplant patients , flow -cytometry 
based minimal residual disease (MRD) detection for AML has been shown to be highly predictive of relapse and overall survival (OS).
8-10 Molecular 
analyses of leukemia fusion genes can also allow for disease monitoring in select patients,
11 and persistence of a cytogenetic abnormality at the time 
of transplantation is a poor predictor for relapse and OS after a myeloablative HSCT.
12  
 Developing clinical trials for AML post-allogeneic HSCT patients with 
imminent or high- risk of relapse is an area of active interest that warrants 
further exploration using novel therapies.  
3.1 Background and Rationale  
The H edgehog (Hh) signaling pathway regulates essential elements 
of embryonic development , homeostasis and tissue regeneration 
and development .
15 It is important in a broad range of cancers, 
including basal cell carcinoma, bladder, colorectal, lung, pancreas, prostate and stomach.
16  Hh signaling is activated by binding of one 
of three Hh ligands , Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), 
or Desert Hedgehog (Dhh) to their receptor, Patched (Ptch).17 
Binding of Hh ligand to Ptch alleviates repression of a second transmembrane protein, Smoothened  (SMO ), allowing SMO  to 
transduce the signal to the cytoplasm resulting in activation of Gli 
family zinc finger transcription f actors ( Gli1, Gli2 and Gli3 ). Gli 
translocates into the nucleus and activates transcription of target genes, causing proliferation.  
 
Activation of the Hh pathway can occur by two mechanisms. First, 
mutations in Ptc h or SMO  genes result in constitutive activation of 
the pathway and upregulation of Gli. Mutations in Hh signaling members have been reported in basal cell carcinoma, 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 5 medulloblastoma, and rhabdomyosarcoma.18,19 A direct link between 
mutation driven aberrant Hh signaling and human tumorgenesis is 
found in Gorlin Syndrome ,18 characterized by the development of  
multiple basal cell carcinomas, and are predisposed to medulloblastoma and rhabdomyosarcoma. These patients have a germline inactivating mutation in the repressor Ptc h that results in 
constitutively active SMO and upregulation of Hh target genes. The 
link between mutations in Ptc h and basal cell carcinoma was also 
reported in a majority of sporadic basal cell carcinoma tumors ,
18,19 
and a significant numbe r of sporadic medulloblastomas can also be 
attributed to inactivating mutations in Ptch.19 To test these findings, 
a genetically engineered mouse model of  medulloblastoma was 
developed by genomic deletion of a Ptc h allele ;20,21 the heterozygous 
Ptch deletion mutation, coupled with a deletion of p53, resulted in 
posterior fossa  tumors with active Hh pathway signaling and 
upregulated expression of Gli target genes .22  
 
The second method of Hh activation is through autocrine or paracrine mechanisms of ligand driven Hh pathway activation in adult tissues with a normally dormant Hh pathway. In some cancers Hh pathway members are expressed in the  tumor cells and directly affect the 
growth of the tumor, resulting in an autocrine positive feedback loop. In other cases, Hh ligand produced by tumor cells may activate the pathway in adjacent stroma, leading to the release of growth factors that support  tumor growth or angiogenesis as part of the tumor 
microenvironment .
23  
 The Hh pathway is now recognized for its involvement in the 
maintenance, growth and drug resistance of hematological malignancies. Hh pathway signaling is preferentially activated in 
MDS -derived cells and CD34
+ AML blasts and cell lines,  24-26 
including chemoresistant cell lines,27  and p atient derived AML 
samples express Gli -1 in proportion to the number of CD34+ blast 
cells (Jamieson et al, manuscript in preparation) , suggesting 
aberrant Hh signaling may contribute to the survival and expansion of the leukemia stem cell. Hh signaling is also relevant in B -cell ALL
28 
and pot entially T -cell ALL,29,30 and can be modulated by pathway 
inhibitors, which were also shown to limit the self -renewal  of 
leukemia cells.28  In addit ion, it was recently shown that inhibiting the 
Hh pathway can selectively eliminate leukemia stem cells  (LSCs).31 
Therefore, given the central role that Hh signaling plays in cell differentiation, Hh inhibition represents a mechanistically novel approach to eliminate the LSC population and thus abrogate tumor proliferation in at least a subset of CD34+ myeloid driven 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 6 hematopoietic  malignancies , making this pathway an attractive 
target for residual, treatment resistant disease.  
 
PF-04449913 (Pfizer) is a novel small molecule inhibitor of the Hh 
pathway that bi nds and inhibits SMO .  This ultimately results in 
ubiquination of Gli 1/2, leading to degradation and clearance of these 
transcription factors.  Early phase clinical trials using this agent has 
shown it to be well tolerated and effective in patients with hematological malignancies.
32 
 
Hypothesis  
 
PF-04449913 will be well -tolerated and effective therapy for acute 
myeloid leukemia patients who have received HSCT and have high 
risk of disease relapse. We aim to test  this hypothesis with this phase 
2 clinical study.  
 
3.2 PF-04449913  
Cyclopamine, isolated from the corn lily plant , interacts  with and 
inhibit s SMO .33 PF-04449913 was synthesized to improve the 
hepatic clearance, decrease the lipophilicity and increase the 
solubility  of cyclopamine. PF-04449913 is a potent and selective 
inhibitor of Hedgehog (Hh) signaling in vitro  and has demonstrated 
significant antitumor efficacy in vivo .  
 
Chemical Structure of PF -04449913  
Molecular weight: 374.439 daltons  
Chemical name: 1-((2R,4R)-2- (1H-benzo[d]imidazol -2-yl)-1- 
methylpiperidin-4- yl)-3-(4-cyanophenyl)urea 
dihydrochloride monoh ydrate 
Molecular Formula: C21H26Cl2N6O2 (dihydrochloride 
monohydrate)  
Physical description: White to pale- colored powder  

 C o nfi d e nti al    
    
       
 
C O MI R B # 1 2 -1 5 5 8 - V er si o n # 7 : 1 5 O C T 2 0 1 9  7  Bi o a v ail a bilit y: Or al  
Pr e -Cli ni c al D at a  
P h ar m a c o ki n eti c s/ P h ar m a c o d y n a mi c s a n d M et a b oli s m  
Pr e cli ni c al  p h ar m a c o ki n eti c  ( P K)  / p h ar m a c o d y n a mi c s  ( P D)  
m o d eli n g s u g g e st s a t ar g et h u m a n d o s e of 1 5 m g/ d a y i s pr oj e ct e d t o 
yi el d at l e a st 5 0 % of t u m or Gli 1 m R N A i n hi biti o n fr o m b a s eli n e l e v el s. A 1 5 m g d o s e i s pr oj e ct e d t o r e s ult i n a C mi n of 6 2 n g/ m L t ot al ( 5. 6 n g/ m L fr e e) a n d a C a v e of 7 9 n g/ m L t ot al ( 7. 2 n g/ m L fr e e).  
A b s ol ut e  or al  bi o a v ail a bilit y  of  P F -0 4 4 4 9 9 1 3  f oll o wi n g  si n gl e  d o s e 
or al a d mi ni str ati o n w a s 3 3 % i n r at s a n d 6 8 % i n d o g s. Pl a s m a pr ot ei n 
bi n di n g  of  P F -0 4 4 4 9 9 1 3  i n  m o u s e,  r at,  d o g,  a n d  h u m a n  pl a s m a 
r a n g e d fr o m  8 5 %  t o  9 3 %.  A  v ol u m e of di stri b uti o n  at  st e a d y  st at e ( V s s)  of  4. 7 8  a n d  4. 2 1  L/ k g  w a s  o b s er v e d  i n  r at s  a n d  d o g s, r e s p e cti v el y.  
P F -0 4 4 4 9 9 1 3  w a s  e v al u at e d  i n  r at  a n d  d o g  r e p e at -d o s e  t o xi cit y 
st u di e s u p t o 1 m o nt h i n d ur ati o n. P F -0 4 4 4 9 9 1 3 w a s w ell t ol er at e d 
u p t o 5 0 m g/ k g/ d a y  i n t h e r at a n d 5 m g/ k g/ d a y i n t h e d o g. I n b ot h t h e 
r at  a n d  t h e  d o g,  a  gr e at er  t h a n  pr o p orti o n al  i n cr e a s e  i n  e x p o s ur e o c c urr e d wit h i n cr e a si n g d o s e. I n t h e r at st u d y, t h e i n cr e a s e i n m e a n 
A U C( 0 -2 4) v al u e s w er e a p pr o xi m at el y 1 7 5 -f ol d a n d 2 3 2-f ol d gr e at er 
t ha n  t h e  d o s e  ( 5 0 -f ol d)  r a n g e  e v al u at e d  f or  D a y  1  a n d  D a y  2 9, r e s p e cti v el y. I n t h e 1-m o nt h d o g t o xi cit y st u d y, t h e m e a n A U C( 0 -2 4) 
v al u e s  w er e  a p pr o xi m at el y  1 6 5 -f ol d  ( m al e)  a n d  3 6 0-f ol d  (f e m al e) 
gr e at er t h a n t h e d o s e ( 3 0 -f ol d) r a n g e e v al u at e d o n D a y 1.  
I n  vitr o m et a b oli s m  of  P F -0 4 4 4 9 9 1 3  w a s  c o n si st e nt  a cr o s s 
pr e cli ni c al s p e ci e s a n d h u m a n s. All m et a b olit e s o b s er v e d i n h u m a n 
i n  vitr o i n c u b ati o n s  w er e  pr e s e nt  i n  o n e  or  m or e  of  t h e  e v al u at e d 
pr e cli ni c al  s p e ci e s.  P F -0 4 4 4 9 9 1 3  a p p e ar e d  t o  b e  m et a b oli z e d  t o 
s e v er al o xi d ati v e  m et a b olit e s.  Pr eli mi n ar y  a s s e s s m e nt  u si n g 
i n di vi d u al r e c o m bi n a nt P 4 5 0 e n z y m e s s u g g e st s t h at C Y P 3 A 4 pl a y s 
a m aj or r ol e i n m e di ati n g t h e m et a b oli s m of P F -0 4 4 4 9 9 1 3 i n vitr o. 
P F -0 4 4 4 9 9 1 3 w a s e v al u at e d i n vitr o i n h u m a n li v er mi cr o s o m e s f or 
t h e p ot e nti al t o i n hi bit C Y P e n z y m e s. Pr eli mi n ar y r e s ult s s h o w t h at 
P F -0 4 4 4 9 9 1 3  d o e s  n ot  i n hi bit  C Y P 1 A 2,  C Y P 2 C 8,  C Y P 2 C 9, 
C Y P 2 C 1 9, C Y P 2 D 6, or C Y P 3 A 4 at c o n c e ntr ati o n s u p t o 3 0 μ M ( 1 1. 2 
 g/ m L).  
I n cr y opr e s er v e d h u m a n h e p at o c yt e s, P F -0 4 4 4 9 9 1 3 d o e s n ot i n d u c e 
C Y P 1 A 2 or C Y P 3 A 4 m R N A l e v el s a n d e n z y m e a cti viti e s at u n b o u n d 
c o n c e ntr ati o n s u p t o 1 0 0  M ( 3 7. 4  g/ m L). C o n si d eri n g t h e h u m a n p h ar m a c o ki n eti c s o b s er v e d t o d at e , P F -0 4 4 4 9 9 1 3 i s n ot e x p e ct e d t o 
 C o nfi d e nti al    
    
       
 
C O MI R B # 1 2 -1 5 5 8 - V er si o n # 7 : 1 5 O C T 2 0 1 9  8  r e d u c e pl a s m a  c o n c e ntr ati o n s  of  c o -a d mi ni st er e d  C Y P 1 A 2  or 
C Y P 3 A 4 s u b str at e s i n vi v o. 
   T o xi cit y  
D e at h s a n d/ or m ori b u n d e ut h a n a si a o c c urr e d i n t h e 7 -d a y a n d 1 0 -d a y r at, a n d 1 -m o nt h d o g st u di e s at 2 5 0, 5 0 0 or 3 0/ 1 5 m g/ k g/ d a y, 
r e s p e cti v el y. C a u s e of d e at h/ m or bi dit y i n b ot h s p e ci e s w a s attri b ut e d t o ki d n e y t o xi cit y. T h e t ar g et or g a n i n t h e r at 1-m o nt h t o xi cit y st u d y 
i n cl u d e d  ki d n e y  (t u b ul ar  d e g e n er ati o n/ n e cr o si s,  c yt o m e g al y, 
i nfl a m m ati o n,  r e g e n er ati o n)  a n d  b o n e  ( d e cr e a s e d/ di s or g a ni z e d c h o n dr o c yt e s  i n  e pi p h y si s);  t h e  n o  o b s er v e d  a d v er s e  eff e ct  l e v el 
( N O A E L) w a s 1 0 m g/ k g/ d a y ( a 5 × s af et y m ar gi n o v er t h e pr oj e ct e d 
h u m a n  C a v e  at  st e a d y  st at e).  T h e  ki d n e y  c h a n g e s  s h o w e d  s o m e si g n s  of  r e v er si bilit y  b ut  di d  n ot  e ntir el y  r e v er s e,  w hil e  t h e  b o n e c h a n g e s p er si st e d.  
T h e t ar g et org a n i n t h e 1 -m o nt h t o xi cit y st u d y i n t h e d o g w a s li mit e d 
t o  t h e  ki d n e y  (t u b ul ar  n e cr o si s,  gr a n ul ar/ mi n er ali z e d  c a st s,  dil at e d 
t u b ul e s); N O A E L w a s 1 m g/ k g/ d a y w hi c h i s < 1 × t h e pr oj e ct e d h u m a n 
C a v e at st e a d y st at e. Mil d c h a n g e s i n t h e ki d n e y w er e o b s er v e d at  5 m g/ k g/ d a y w hi c h ar e 1 1 × t h e pr oj e ct e d h u m a n C a v e at st e a d y st at e. 
T h e ki d n e y c h a n g e s i n t h e d o g w er e c o m pl et el y r e v er s e d i n m al e s 
a n d p arti all y r e v er s e d i n f e m al e s aft er a 6 -w e e k r e v er s al p eri o d. I n t h e a c ut e c e ntr al n er v o u s s y st e m ( C N S) a n d r e s pir at or y st u di e s i n 
t h e r at, n o eff e ct s w er e o b s er v e d at t h e hi g h d o s e of 5 0 m g/ k g ( 5 5 × 
a b o v e  t h e  pr oj e ct e d  h u m a n  effi c a ci o u s  C mi n  at  st e a d y  st at e). I n cr e a s e s i n Q T, Q T c 7 5 w er e n ot e d aft er si n gl e d o s e s of  5 m g/ k g 
t o d o g s w hi c h i s  4 9 ×  a b o v e t h e pr oj e ct e d h u m a n effi c a ci o u s C m a x 
at st e a d y st at e. P F -0 4 4 4 9 9 1 3 w a s n e g ati v e i n t h e d efi niti v e i n vitr o 
b a ct eri al  m ut a g e ni cit y  a s s a y,  h u m a n  l y m p h o c yt e  a s s a y  a n d  t h e i n vi v o  r at  mi cr o n u cl e u s.  T h e  m ol ar  e xti n cti o n  c o effi ci e nt  f or  P F-
0 4 4 4 9 9 1 3 at 2 9 0 n m i s 9 6 2 2 L/ m ol/ c m; t h er ef or e, P F -0 4 4 4 9 9 1 3 h a s 
t h e p ot e nti al t o b e p h ot ot o xi c. 
T o e v al u at e  p ot e nti al  eff e ct s  o n  t h e  c e ntr al  n er v o u s  s y st e m,  P F -
0 4 4 4 9 9 1 3 w a s a d mi ni st er e d a s a si n gl e d o s e t o m al e r at s, a n d m ot or a cti vit y,  b e h a vi or al  c h a n g e s,  c o or di n ati o n,  s e n s or y/ m ot or  r efl e x 
r e s p o n s e s,  a n d  b o d y  t e m p er at ur e  w er e  e v al u at e d.  T h er e  w er e  n o 
eff e ct s  i n  eit h er  t h e  f u n cti o n al  o b s er v ati o n al  b att er y  or  l o c o m ot or a cti vit y a s s e s s m e nt at d o s e s u p t o 5 0 m g/ k g. T h e m a xi m u m pl a s m a 
c o n c e ntr ati o n at 5 0 m g/ k g fr e e gr o u p m e a n C m a x of 6 1 7 n g/ m L fr o m 
t h e 1-m o nt h r at i s 7 2 -f ol d a b o v e t h e pr oj e ct e d h u m a n fr e e effi c a ci o u s C m a x c o n c e ntr ati o n of 8. 6 n g/ m L. T o e v al u at e t h e p ot e nti al eff e ct o n 
t h e c ar di o v a s c ul ar s y st e m, P F-0 4 4 4 9 9 1 3 w a s e v al u at e d f or it s eff e ct 
o n  bi n di n g  t o  t h e  h E R G  p ot a s si u m  c h a n n el  st a bl y  e x pr e s s e d  i n h u m a n  e m br y o ni c  ki d n e y  ( H E K -2 9 3)  c ell s 
 C o nfi d e nti al    
    
       
 
C O MI R B # 1 2 -1 5 5 8 - V er si o n # 7 : 1 5 O C T 2 0 1 9  9  ( P F 4 4 4 9 9 1 3/ E S D/ 1 1 0 8/ H E R G).  T h e  h E R G  I C 5 0  f or  P F-0 4 4 4 9 9 1 3 
w a s  3. 1  M  w hi c h  i s  1 6 3 -f ol d  a b o v e  t h e  pr oj e ct e d  fr e e  h u m a n 
effi c a ci o u s ( C a v e) dr u g c o n c e ntr ati o n of 1 9 n M a n d 1 3 5 -f ol d a b o v e t h e  pr oj e ct e d  h u m a n  fr e e  effi c a ci o u s  C m a x  ( 2 3  n M).  T o  f urt h er 
i n v e sti g at e Q T pr ol o n g ati o n a n d a n y h e m o d y n a mi c c h a n g e s d u e t o 
i n hi biti o n  of  s e v er al  r e c e pt or s  o utli n e d  i n  t h e  s e c o n d ar y p h ar m a c o d y n a mi c s s e cti o n, P F -0 4 4 4 9 9 1 3 w a s a d mi ni st er e d b y or al 
g a v a g e t o c o n s ci o u s t el e m et eri z e d d o g s  at d o s e l e v el s of 1, 5 a n d 
3 0 m g/ k g. At d o s e l e v el s of 5 a n d 3 0 m g/ k g, P F -0 4 4 4 9 9 1 3 pr o d u c e d a  st ati sti c all y  si g nifi c a nt  a n d  d o s e  d e p e n d e nt  i n cr e a s e  i n  Q T  a n d 
Q T c 7 5 w hi c h w a s a p p ar e nt u p t o at l e a st 1 4 h o ur s p o st -d o si n g. T h e 
m a xi m u m o b s er v e d Q T c 7 5 pr ol o n g ati o n w a s 6 a n d 2 4 m s e c at 5 a n d 3 0 m g/ k g, r e s p e cti v el y. I n cr e a s e s i n h e art r at e ( 1 0 b e at s p er mi n ut e) 
o c c urr e d i n t h e 3 0 m g/ k g tr e at e d d o g s w hi c h w er e c oi n ci d e nt wit h 
e pi s o d e s  of  e m e si s a n d  ar e  m o st  li k el y  r el at e d  t o  t h e  l att er eff e ct. T h er e w a s al s o a s m all i n cr e a s e ( 3 m s e c) i n t h e Q R S i nt er v al aft er 
t h e 3 0 m g/ k g tr e at m e nt a n d t hi s w a s a p p ar e nt u p t o 1 4 h o ur s p o st-
d o si n g. T hi s l att er eff e ct i s c o n si st e nt wit h t h e w e a k s o di u m c h a n n el i n hi biti o n  o b s er v e d  i n  a  f u n cti o n al  p at c h  cl a m p  st u d y  ( s e e  t h e 
s e c o n d ar y p h ar m a c o d y n a mi c s s e cti o n). T h er e w er e n o st ati sti c al or 
r e m ar k a bl e c h a n g e s i n d o g s tr e at e d wit h 1 m g/ k g P F-0 4 4 4 9 9 1 3. At 5  m g/ k g,  t h e  p e a k  fr e e  pl a s m a  c o n c e ntr ati o n  i n  m al e  a n d  f e m al e 
d o g s w a s 5 1 7 n g/ m L a n d 4 2 0 n g/ m L, r e s p e cti v el y (fr o m t h e 1 -m o nt h 
d o g). T hi s r e pr e s e nt s a 4 9 t o 6 0 -f ol d m ar gi n a b o v e t h e pr oj e ct e d fr e e C m a x  ( 8. 6  n g/ m L)  at  a  h u m a n  effi c a ci o u s  d o s e  of  1 5  m g.    P F -
0 4 4 4 9 9 1 3 w a s a d mi ni st er e d a s a si n gl e d o s e t o m al e r at s t o a s s e s s 
p ot e nti al  eff e ct s  o n  t h e  r e s pir at or y  s y st e m.  P F -0 4 4 4 9 9 1 3  h a d  n o eff e ct  o n r e s pir at or y r at e, ti d al v ol u m e or mi n ut e v ol u m e at d o s e s u p 
t o 5 0 m g/ k g. T h e m a xi m u m pl a s m a c o n c e ntr ati o n at 5 0 m g/ k g (fr e e 
m e a n C m a x of 6 1 7 n g/ m L fr o m t h e 1 -m o nt h r at i s 8 6 -f ol d a b o v e t h e pr oj e ct e d h u m a n ( C a v e) dr u g c o n c e ntr ati o n of 7. 2 n g/ m L a n d 7 2 -fol d a b o v e t h e pr oj e ct e d h u m a n fr e e effi c a ci o u s C m a x ( 8. 6 n g/ m L).  
 
Cli ni c al D at a  
S e e c urr e nt  P F -0 4 4 4 9 9 1 3  I n v e sti g at or ’ s Br o c h ur e   – r el e a s e d  b y 
Pfi z er ( m a n uf a ct ur er) . 
 
S e v er al cli ni c al st u di e s h a v e b e e n i niti at e d t o d et er mi n e t h e s af et y, effi c a c y, p h ar m a c o d y n a mi c s a n d p h ar m a c o ki n eti c s of P F -0 4 4 4 9 9 1 3 i n p ati e nt s wit h h e m at ol o gi c m ali g n a n ci e s a n d a d v a n c e d/ m et a st ati c s oli d t u m or s. St u d y B 1 3 7 1 0 0 1 w a s a fir st -i n-p ati e nt p h a s e  1 tri al wit h a 3 + 3 d o s e e s c al ati o n d e si g n i n p ati e nt s wit h r efr a ct or y, r e si st a nt or i nt ol er a nt s el e ct h e m at ol o gi c m ali g n a n ci e s. P ati e nt s r e c ei v e d si n gl e 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 10 agent PF -04449913 orally once daily (QD) continuously in 28 day 
cycles. Eight dose levels were evaluated as of September 2011, 
ranging from 5 mg/d to 270 mg/d. Study B1371002 had a similar 3+3 dose escalation design in patients with select advanced/metastatic solid tumors. The starting dose of PF -04449913 in this study was 80 
mg/d and additional dose levels of 160 mg/d and 320 mg/d have been completed to date. Protocol B1371003, a Phase 1b/2 study to evaluate the safety and efficacy of PF -04449913 in combination with 
various chemotherapy regimens in patients with AML and high- risk 
MDS, is ongoing.  
 
Pharmacokinetics/Pharmac odynamics and Metabolism  
Preliminary PK data indicate that PF -04449913 is rapidly absorbed 
following oral dosing with a median Tmax of ~1- 2 hr after single and 
multiple dose administration. Following attainment of Cmax , PF-
04449913 plasma concentrations showed a bi -exponential decline 
and were eliminated relatively slowly with a mean terminal half -life 
(estimated from a single dose) ranging from 17.3 to 34.9 hours. 
Following repeated daily dosing, PF -04449913 steady sta te was 
achieved by Day 8 and showed a drug accumulation of ~ 1.5 fold, 
which is consistent with the estimated half -life. In general, low to 
moderate inter -individual variability were observed in Cmax and AUC 
values following single and multiple dose administration, though 
higher variability was observed at the 180 and 270 mg dose levels.  
 Hepatic metabolism is predicted to be the major clearance pathway 
for PF -04449913 in humans. In vitro metabolism of PF -04449913 
was consistent across preclinical species and humans. PF -
04449913 appeared to be metabolized to several oxidative metabolites. Preliminary assessment using individual recombinant 
P450 enzymes suggests that CYP3A4 plays a major role in mediating the metabolism of PF -04449913. All metabolites observ ed 
in human in vitro incubations were present in one or more of the evaluated preclinical species. In vitro, PF -04449913 did not inhibit 
CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at 
concentrations up to 30 μM. Based on in vitro and in vivo evaluat ions 
of PF -04449913, systemic plasma clearance, volume of distribution 
at steady state, elimination half -life and oral bioavailability in humans 
are projected to be 1.03 mL/min/kg, 2.7 L/kg, 30 hours and 55%, 
respectively.  
 
Preliminary data indicates that  renal excretion plays a minor role in 
PF-04449913 elimination, with 4% to 19% (n = 15) of the total 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 11 administered dose excreted unchanged in urine. The renal clearance 
ranged from 0.35 L/hr to 3.4 L/hr. 
 When 200 mg PF -04449913 was combined with ketoconazole, a 
strong inhibitor of CYP3A4, in healthy volunteers, there was evidence for a drug -drug interaction resulting in increased exposure 
(Cmax and AUC) of PF -04449913, potentially to the 400- 600 mg 
range observed to result in grade 3 QTc prolongations in st udy 
B1371001.  
 Study B1371010, a healthy volunteer study investigating the effects of a high fat, high calorie meal on the PK of a single dose of PF -
04449913, indicated that food resulted in a 12.7% decrease in AUC and a 34.1% decrease in Cmax for PF -0444 9913.  
 
Toxicity  
Preliminary results  from a phase 1 study in patients with 
hematological malignancies revealed grade 3 toxicities of 
hemorrhagic gastritis, hypoxia and pleural effusions. All other 
adverse events (AEs) were less than grade 3, and included dysguesia (16%), alopecia (6%), arthralgia (6%), decreased appetite 
(6%), nausea (6%) and vomiting (6%).32 Roughly 50% of patients 
had at least a grade 1 AE. This study and others are ongoing.  
 
Recommended Dose  
Due to the potential interaction between azoles and PF -04449913, 
100 mg of PF -04449913 has been selected as the recommended 
dose in the ongoing protocol B1371003.  
4 STUDY OBJECTIVES  
4.1 Primary Objective  
 Determine whether PF -04449913 can prevent relapse in high 
risk acute myeloid leukemia patients who receive an 
allogeneic stem cell transplantation  
4.2 Secondary Objective s 
 Determine the toxicity profile of PF -04449913 in this 
population  
 Determine the impact of this intervention on overall survival 
(OS) 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 12 5 INVESTIGATION AL PLAN  
5.1 Overall Study Design  
This is  an open- label, phase 2 study  of PF-04449913 administered 
to acute myeloid leukemia patients after allogeneic stem cell 
transplantation who have a high risk of disease relapse. 
 
5.1.1  Dosing Schema  
Enrolled patients will  receive 100 mg PO daily of PF -
04449913 continuously dosed for 28- day cycles .  Patients will 
begin treatment no sooner than post -transplant day 28 and no 
later than post -transplant day 50, after their routine bone 
marrow biopsy is performed. Treatment cycles can continue 
for one year after initiation of study drug in the absence of the 
parameters listed in Section 5.10.1: Stopping Rules.  
 
5.1.2  Continuation and Interruptions   
Each treatment cycle will be initiated at the full 100 mg dose, 
provided patients  have no evidence of disease relapse, 
excessive toxicity, or laboratory values outside of the following parameters:   
 
• Either creatinine >1.5 x institutional upper limit of normal (ULN)  or creatinine clearance < 60 mL/min as 
calculated by institution’s standard formula  
• Total bilirubin > 2 x ULN (unless documented Gilbert’s 
syndrome)  
• AST and ALT > 5 x institutional ULN  
• Abso lute neutrophil count (ANC) < 10 00/mm
3  
• Platelet count <2 5,000/mm3  
 
Patients who experience toxicity may be eligible for dose de-
escalation; please see Section 5.13.1 for Definition of Adverse 
Events  and Section 5.10.2. 2: Dose Delays and De-Escalation. 
5.2 Study Endpoints  
5.2.1  Primary Endpoint  
• One year relapse- free survival  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 13 5.2.2  Secondary Endpoints  
• Remission durat ion 
• Incidence and severity of adverse events  
• O verall survival  (one year)  
 
5.3 Selection of Study Population and Enrollment Procedures 
All subjects will be screened for eligibility; see Section 2: Schedule 
of Study Assessments and Section 5.12:  Study Activities and 
Assessment s for screening details. All patients must meet the 
qualifications as outlined below.  
 
5.3.1  Inclusion Criteria  
To be eligible to participate in this study, a patient must meet 
the following criteria:  
• WHO -confirmed AML 
• Age ≥18 years  
• Between days  28 and 50 post transplant ation  at the time 
of initiation of the study drug  
• ECOG performance status ≤ 2 (See Appendix A: ECOG 
Performance Status Scale)  
• Life expectancy > 2 months  
• Recipient of a myeloablative or non- myeloablative 
allogeneic HSCT  
o Conditioni ng regimen to be prescribed at 
investigator’s discretion, but will be prospectively defined as myeloablative or non- myeloablative 
• Stable engraftment , as defined by absolute neutrophil 
count (ANC) ≥ 1000/mm
3 and platelets ≥ 25,000/mm3 
• In morphologic remission (< 5% marrow blasts)  based on 
BM biopsy performed +/ - 5 days of day 28 post -
transplantation  
• W ithout clinical signs of active central nervous system 
disease   
• For non- myeloablative transplants, ≥50% CD3 donor 
chimerism at screening 
• High risk of re lapse after HSCT, defined as the presence 
of minimal residual disease as measured by flow 
cytometry in the absence of evidence of morphologic disease on a bone marrow biopsy prior to HSCT  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 14 • A dequate organ function as indicated by the following 
laboratory values:  
o A spartate aminotransferase (AST), alanine 
aminotransferase, (ALT) ≤ 3.0 x institutional upper 
limit of normal (ULN)  
o Total bilirubin ≤ 2.0 x institutional ULN , unless 
documented Gilbert’s syndrome  
o Either cre atinine <1.5 x institutional upper limit of 
normal (ULN) or creatinine clearance >60 mL/min as calculated by institution’s standard formula  
• Serum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiat ion 
of first dose of treatment (a patient is of childbearing 
potential if, in the opinion of the investigator, she is 
biologically capable of having children and is sexually active ) 
• F emale patients of childbearing potential and sexually 
active males and fe male partners of childbearing potential 
must agree to use a highly effective method of contraception throughout the study and for at least 90 days after the last dose of assigned treatment.  
• Subject is able to comply with study procedures and follow -up exam inations.  
 
5.3.2  Exclusion Criteria  
 
• Concomitant treatment with other anti -neoplastic agents , 
with the exception, when clinically indicated, of prophylaxis in the post -transplantation setting with intrathecal 
chemotherapy  
• Use of any other experimental drug or therapy within 28 days of baseline  
• Inability to swallow or absorb drug  
• Active  uncontrolled  acute fungal, bacterial, or other 
infection that is unresponsive to therapy  at time of  study 
drug dosing  
• Unstable angina pectoris  
• New York Heart Association Class II I or IV heart failure  
• QTc interval  (using Fridericia’s correction formula, QTcF , 
if prolonged) >470 msec  
• Active c ardiac arrhythmias with rapid ventricular response 
(defined as heart rate greater than 100 beats/minute)  
• Known HIV infection  
• Grade III/IV acute  GVHD  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 15 • Current use or anticipated need for food or drugs that are 
known moderate/ strong CYP3A4 inducers  (See Table 1 
and section 5.9.2 : Prohibited Concomitant Therapy ), with 
the exception of azole antifungals, which are permitted.  
• A ny medical, psychiatric, addictive or other kind of 
disorder which compromises the ability of the subject to 
give written informed consent and/or to comply  with 
procedures.  
• Pregnant or lactating females  
 
5.3.3  Lifestyle Guidelines  
All male and female patients who, in the opinion of the investigator, are biologically capable of having children and are sexually active, must agree to use a highly effective method of contraception consistently and correctly for the duration of the active treatment period and for at least 90 days after the last dose of investigational product. The investigator, in consultation with the patient, will select the most appropriate method of contraception for the individual patient from the permitted list of contraception methods, and instruct the patient in its consistent and correct use. The investigator, at each study visit, will confirm and document consistent and correct use. In addition, the investigator will instruct the patient to call immediately if the selected birth control method is discontinued or if pregnancy is known or suspected.  
 Highly effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly ( i.e., perfect 
use) and include:  
 1. Abstinence  
2. Establish ed use of oral, injected or implanted hormonal 
methods of contraception  
3. Correctly placed intrauterine device or intrauterine system  
4. Male condom or female condom used with a spermicide 
(i.e., foam,  gel, film, cream, suppository)  
5. Male sterilization with appropriately confirmed absence of sperm in the post - vasectomy ejaculate  
6. Bilateral tubal liga tion or bilateral salpingectomy  
 In addition, special precautions will be taken to limit any potential photo irritation effect, by minimizing the patients’ 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 16 exposure to light including high intensity UVb sources such as 
tanning beds, tanning booths and sunlamps. Patients should be advised to apply sunscreen/sunblock daily, and will be 
advised to report any reaction to sun exposed skin.  
 
5.4 Duration of Stu dy 
All patients will be followed for 30 days after the last study treatment, 
and with annual phone calls for five years .  It is anticipated that the 
study will be completed within four to five  years.   
 
5.5 Drug Administration 
5.5.1  Premedication  
No premedication is re quired.  
 
5.5.2  PF-04449913  
 
PF-04449913 will be provided to research subjects for the 
duration of their participation in this trial by Pfizer at no charge 
to them or their insurance providers .  PF-04449913 is 
formulated in tablets containing 10 mg, 25 mg and 100 mg of study medication. The tablets are packaged in high- density 
polyethylene bottles, with protection from moisture and should be handled with care. Site personnel must ensure that patie nts clearly understand the directions for self -medication. 
Patients should be given sufficient supply to last until their next study visit. Patients should be instructed to keep their medication in the bottles provided and not transfer it to any other containers. PF -04449913 will be administered once 
daily and orally on a continuous basis for all patients. A cycle is defined as 28 days, regardless of missed doses or dose delays. PF -04449913 will be administered without adjustment 
for body size and irrespective of PO intake. Tablets must not 
be crushed or cut; they must be swallowed whole and not chewed. Patients should be instructed to self -administer their 
medication in the morning at approximately the same time each day and to not take more than the prescr ibed dose at 
any time. If a patient misses a day’s dose entirely, they must be instructed not to “make it up” the next day. If a patient vomits any time  after taking a dose, they must be instructed 
not to “make it up,” but to resume subsequent doses the next 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 17 day as prescribed. If a patient inadvertently takes 1 extra dose 
during a day, the patient should not take the next dose of PF -
04449913. If a medication error is accompanied by an AE, 
such as an overdose (accidental or intentional), as determined by the investigator, the AE is captured on an AE 
CRF page (see Section 5.13.3: Procedures for Recording Adverse Events).  
 
5.6 Assuring Patient Compliance 
Patients will receive all dosages of PF-04449913 by self -
administration in the outpatient setting , and will be instructed to 
continue if admitted to the hospital for reasons other than drug -
related toxicity. Patients will receive a diary to record the specific time each dose was taken and to record reasons for any missed doses.  
Patient compliance will be assessed on day 1 of cycles 2 and every 
cycle thereafter .  Patients will be required to bring their diary and any 
remaining pills to clinic during this  visit.  Research personnel will 
count and record the number of used and unused drug at each visit and reconcile with the patient diary.  Any unused PF-04449913 will 
be returned  in compliance with 21 CFR 312.59. 
 
5.7 Laboratory Criteria for Initiation of Treatment Cycles 
 
Before any treatment cycle after cycle 1 may be administered, blood 
samples collected within 72 hours of the first dose of each cycle must 
meet the following criteria:  
 
• Either creatinine ≤ 1.5 x ULN  or creatinine clearance ≥ 60 mL/min 
as calculated by institution’s standard formula  
• Total bilirubin ≤ 2 x institutional ULN (unless documented Gilbert ’s syndrome)  
• AST and ALT ≤ 5 x institutional ULN  
• ANC > 1000/mm
3  
• P latelets > 25,000/m3 
 
5.8 Study Treatment Schedule 
 
Patients will receive study t reatment as detailed in Section 5.1: 
Overall Study Design, and assessments will be performed as outlined in Section 2: Schedule of Study Assessments.  Routine 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 18 disease assessments, as dictated by usual standard of care, will 
occur ; there are no study -specific disease assessments.  Patients 
will be taken off of the study if they meet criteria listed in Section 
5.10.1: Stopping Rules.   
 
5.9 Concomitant Therapy 
5.9.1  Permitted Concomitant Therapy  
Transfusion of blood and blood products, antibiotics,  
antiemetics and other standard supportive care medications 
are permitted if necessary.   Azole antifungals (f luconazole, 
voriconazole, posaconazole, itraconazole and ketoconazole) may be used.  
 
5.9.2  Prohibited Concomitant Therapy  
Chemotherapy, immunotherapy and radiotherapy are prohibited.   
 
The following information is based on results from in vitro studies with PF -04449913 and a drug-drug interaction study 
with a strong CYP3A4/5 inhibitor in healthy subjects.  
 CYP3A4/5 Inhibitors: Because inhibition of CYP3A4/5 
isoenzymes were expected to increase PF -04449913 
exposure and the extent of this interaction in humans was  
unknown, the use of moderate/strong CYP3A4/5 inhibitors 
was previously  prohibited. In a healthy volunteer study, 
ketoconazole, a potent CYP3A4/5 inhibitor,  produced a 2.4-
fold increase in plasma exposure and a 1.4- fold increase in 
peak  plasma concentration of PF-04449913. Therefore a 
potential exists for drug -drug interactions with CYP3A4/5 
inhibitors, and co- administration of PF -04449913 in  
combination with moderate/strong CYP3A4/5 inhibitors is not recommended.  Selection of concomitant medication with no 
or m inimal CYP3A4/5 inhibition  potential  is recommended. 
Moderate CYP3A4/5 inhibitors ( Table 1) should be used with 
caution and only if considered medically necessary. If a  
moderate/strong CYP3A4/5 inhibitor is to be initiated in addition to PF -04449913,  the guidance provided in Section 
5.12.5.5 requiring additional EKG monitoring before,  during 
and after starting the medication, electrolyte monitoring (including correction and re- checking values) and dose 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 19 modifications for QTcF prolongation per Section 5.10.2. 2 
must be followed.  Azole antifungals are permitted to be 
administrated concomitantly with PF- 04449913.  
 
CYP3A4/5 Inducers: PF-04449913 metabolism may be 
induced when taking  CYP3A4/5 inducers, resulting in reduced 
plasma concentrations. The impact of  CYP3A4/5 inducers on 
PF-04449913 pharmacokinetics has not been studied in the  
clinic. Therefore co- administration of PF -04449913 in 
combination with any moderate/strong CYP3A4/5 inducers 
(representative medications in Table 1) is not permitted from 
study entry until study treatment discontinuation.  
 Drugs with known risk of Torsade de Pointes (TdP): PF-
04449913 has been shown to have the potential to prolong 
the QTc interval in pre- clinical studies. In the first-in-patient 
study as single agent, Grade 3 QTcF prolongation was observed at the highest doses tested (400 mg and 600 mg). 
While the current clinical dose being  
evaluated in this study is 100 mg, the concomitant administration of PF -04449913 and drugs with known risk of 
torsade de pointes is not recom mended unless there are no  
alternatives. If a TdP  drug is to be initiated in addition to PF -
04449913 the guidance provided in Section 5.12.5.5  
requiring additional EKG monitoring before, during and after starting the medication,  electrolyte monitoring (inc luding 
correction and re- checking values) and dose  modifications for 
QTcF prolong ation per Section 5.10.2.2 must be followed.  QT 
prolonging medications should be avoided whenever possible.  
 
Prior or concurrent treatment with a Hedgehog inhibitor or concurr ent treatment with other investigational agents not 
specified in the protocol is not permitted.  
 Use of warfarin is strongly discouraged if alternate medication (erg, low molecular weight heparin) can be substituted. 
Warfarin is a CYP3A4 substrate and drug  interactions causing 
variability in INR are possible. Frequent monitoring of the INR 
is recommended in subjects taking warfarin. Dosage of 
warfarin should be adjusted as needed.  
5.9.3  Table 1 : Representative prohibited medications based on 
metabolic isoenzyme class.  
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 20 Isoenzyme Class  Representative Drugs  
Strong/moderate 
CYP3A4 inhibitors  aprepitant, clarithromycin, cimetadine, ciprofloxacin, 
conivaptan, diltiazem, erythromycin, fluconazole, 
grapefruit juice, itraconazole, ketoconazole, mibefradil, nefazodone,   posaconazole, telithromycin, tofisopam, 
troleandomycin, verapamil and voriconazole  
(NOTE: antifungal azoles are permitted concomitant 
therapies)  
Strong CYP3A4 
inducers  carbmezapine, phenobarbital, phenytoin, rifampin, 
rifabutin, rifapentin, St. John’s Wo rt 
 
However, because the lists of these agents are constantly changing, it is important to regularly consult a frequently -
updated list such as :  
http://medicine.iupui.edu/clinpharm/ddis/table.aspx
;  
medical reference texts such as the Physicians’ Desk Reference may also provide this information.   
 
5.10 Safety Plan  
Patient safety will be assessed by reviewing AEs during planned 
visits and physical and laboratory examinations from the time the 
patient receives the first dose of study drug until 30 days after the patient’s last study treatment.  See Section 2: Schedule of Study 
Assessments, and Section 5.13: Definitions and Reporting 
Procedures for Adverse Events.   
 
5.10.1  Stopping Rules  
5.10.1.1  Individual Patients’ Stopping Rules  
Patients may be terminated from the study for the following : 
• Noncompliance with the study protocol  
• Morphological disease relapse , defined as having a bone 
marrow biopsy  with > 5% leukemic blasts  on the aspirate 
differential , the presence of peripheral blood blasts or 
extramedullary disease  
• Patient decides to withdraw from the study  
• ≥ Grade 3 AE that is possibly related to the study drug and 
does not resolve or improve within 28 days  (see Section 
5.10.2 .2) 
• Serious AE (SAE)  related or possibly related to the study 
drug; disabilities, hospitalizations, prolongation of 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 21 hospitalizations or required interventions that are related 
to the transplant are excepted  
• Development of unrelated illness  which com promises 
further participation in the study  
• Investigator determines that continuation on study is no longer in the best interest of the patient or a change in the patient’s condition renders them ineligible for further treatment  
• Subject is lost to follow -up despite reasonable efforts by 
the investigator to locate the subject.  
5.10.1.2  Study Stopping Rules  
• The study will be suspended pending further review if, at any time, there is sufficient evidence to suggest that the true probability of hematopoietic toxicity attributable to the drug exceeds 25% or the true probability of severe GVHD exceeds 25%.   Suffic ient evidence will be defined as an 
observed failure rate whose lower one -sided 80% 
confidence limit exceeds the thresholds listed above (25% for hematopoietic toxicity and GVHD).   Operationally, the 
study will be suspended if any of the following proporti ons 
are observed (or exceeded): 3/3- 5, 5/6 -10, 7/11 -15, 9/16-
20, 10/21- 25, 11/26- 28. The probabilities of early 
termination based on this stopping rule for various rates of true toxicity are shown in the table below. The probabilities are based on a simulation with 1,000 replications. 
 
 
    
Probability of Early Stopping Due to Toxicity  
  
  
Number of 
Patients    
True Toxicity Rate  
  
15%  25%  35%  45%  
28  0.0016  0.0693  0.375  0.787  
 
• If any of the above stopping rules is met upon enrollment of the next patient, accrual will be held until it is determined 
that no stopping rules will be met with currently enrolled patients.
 
 
• The study will continue until the last patient is followed 30 
days beyond receiving the last dose of study drug. Annual 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 22 phone calls w ill be made as appropriate for 5 years after 
discontinuation of the study.  
 
5.10.2  Dosing Delays and Modifications  
5.10.2.1  Missed Doses  
Patients will be encouraged to stay on schedule even if a dose 
is missed. Dosing  will be tracked in the patient s’ diaries.  Lack 
of compliance with the study protocol may result in removal 
from the study.  This will be decided on an individual basis by 
the investigators . 
5.10.2.2  Dose Delays and De- escalation  
Patients who experience a ≥ g rade 3 related or possibly 
related non-hematological AE  can have treatment interrupted 
for up to 28 days and restarted at the original dose or reduced 
by 50%, at the discretion of the investigator, if the abnormality 
returns to baseline or ≤ grade 1. An additional 50% dose 
reduction will be permitted for a second episode of a ≥ grade 
3 related or possibly related non- hematological AE. No further 
dose reductions will be permitted. Dose re- escalation by 
100% increments to full dose may be attempted if AEs remain resolved.
  For grade 4 related or possibly related 
hematological toxicities , the dose will be withheld for up to 28 
days, when it returns to ≤ grade 3 it can be resumed at the 
original dose or  reduced 50% at the discretion of the 
investigator.  An additional 50% dose reduction will be permitted for a second episode of a grade 4 related or possibly 
related non- hematological AE. No further dose reductions will 
be permitted. Dose re- escalation by 100% increments to full 
dose may be attempted if AEs remain resolved. Cycles will 
not be prolonged beyond day 28 to make up for missed doses.  
 Treatment  delays beyond 28 days will result in study 
discontinuation.  The dose de- escalation table below is 
provided for guidance.  
 Myalgias and arthralgias  are known to be associated with PF -
04449913, and may be more significant in the post HSCT setting. For patients with ≥ grade 3 myalgias or arthralgias, 
dose interruption will occur until the symptoms resolve to ≤ grade 1. If this does not occur after an i nterruption of 28 days 
the patient will come off of the study. If it does occur within 28 days of interruption, resumption of PF -04449913 will occur at 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 23 the 100 mg dose, but after re- introducti on the drug will be 
given for 21 days consecutively with 7 days off each cycle. If 
a subsequent ≥ grade 3 myalgia or arthralgia event occurs, 
dose interruption will occur until the symptoms resolve to ≤ 
grade 1. If this does not occur after an interruption of 28 days the patient will come off of the study. If it does occur within 28 days of interruption, resumption of PF -04449913 will occur at 
the 50 mg dose, again administered 21 days on and 7 days 
off. Another ≥ grade 3 myalgia or arthralgia event will result in 
the same interruption and resumption schedule as above, this 
time with a dose reduction to 25 mg, and an additional ≥ grade 
3 myalgia or arthralgia event will result in termination of the 
study.  
 
Other toxicities will be managed as follows:  
 
 
Toxicity  
 
Grade 1  or 2 Grade 3   
Grade 4  
 
Continue at 
current dose  Withhold until toxicity returns to ≤ 
grade 1 for related or possibly 
related non hematologic toxicities  
then resume the same dose level 
or reduce by 50%, at the 
discretion of the investigator (nausea, vomiting or diarrhea must persist at grade 3 or 4 despi te maximal medical therapy 
to require a dose reduction).  
One additional 50% dose 
reduction is permitted for a second episode. At the discretion of the investigator, dose re-escalation by 100% increments to full dose may be attempted if 
AEs remain resolved after dose 
reduction (s).  Withhold until toxicity returns to 
≤ grade 1 for related or possibly 
related non hematologic 
toxicities and ≤ grade 3 for 
related or possibly related hematologic tox icities ,  then 
reduce by 50% or discontinue treatment, at the di scretion of 
the investigator (nausea, vomiting or diarrhea must 
persist at grade 3 or 4 despite 
maximal medical therapy to require a dose reduction). One additional 50% dose reduction is permitted for a second episode. At the discretion of the 
investigator , dose re- escalation 
by 100% increments to full dose 
may be attempted if AEs remain resolved after dose 
reduction (s).  
 
  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 24  
Recommended Dose Modifications for Treatment -Related QTcF  
Prolongation  
 
QTcF Prolongation  
 
Grade  
1 2 3 4 
• No 
change  • Withhold study  treatment  
• Assess for and correct 
electrolyte abnormalities.  
• Withhold any concomitant medications that may cause QTcF prolongation.  
• Resume study treatment at prior dose if QTcF returns to ≤470 msec and to within 20 msec of baseline <7 days. β 
• Resume study treatment at one lower dose level if QTcF returns to ≤470 msec and to within 20 msec of baseline between 
7-14 days, or if a prior 
dosing interruption for 
QTcF prolongation has occurred. β 
 Discontinue study 
treatment permanently if: 
• The QTcF prolongation 
does not return to ≤470 ms 
within 14 days.  
• ≥ Grade 2 QTcF prolongation recurs after 
one dose reduction.  
• If anytime during the 14-day window, the patient has a confirmed mean 
QTcF interval >515 ms or 
becomes symptomatic.  • Withhold study treatment  
• Assess for a nd correct 
electrolyte abnormalities.  
• Withhold any concomitant medications that may cause QTcF prolongation.  
• Resume study treatment at prior dose if QTcF returns to ≤470 msec and to within 20 msec of baseline <7 days. β 
• Resume study treatment at one lower dose level if QTcF returns to ≤470 msec and to within 20 msec of baseline between 
7-14 days, or if a prior 
dosing interruption for 
QTcF prolongation has occurred. β 
 Discontinue study 
treatment permanently if: 
• The QTcF prolongation 
does not return to ≤470 ms 
within 14 days.  
• ≥ Grade 2 QTcF 
prolongation recurs after 
one dose reduction.  
• If anytime during the 14-day window, the patient has a confirmed mean QTcF interval >515 ms or becomes symptomatic.
 • Discontinue study treatment permanently
 
QTcF = Fridericia ’s QT correction, ms = milliseconds  
 
β An ECG should be repeated approximately 7 days after study treatment resumption following 
dose  interruption for QTcF prolongation.  
 
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 25  
5.10.3  Data and Safety Monitoring 
AEs and SAEs will be reviewed on an ongoing basis to identify 
safety concerns, and the investigators may discontinue the 
study if excessive toxicity is observed. In addition, the study 
will be monitored by the Cancer Center’s data safety and 
monitoring committee (DSMC) at times designated by the 
committee.  
 
Oversight and Monitoring  
The Principal Investigator will be responsible for monitoring the safety and efficacy of the trial, executing the DSM plan, and complying with all reporting requirements to local and federal authorities. This will be accomplished under the oversight of the Data & Safety Monitoring Committee (DSMC) of the University of Colorado Cancer Center (UCCC).  The DSMC is responsible for monitoring data quality and patient safety for all clinical studies at UCCC.   A summary of the DSMC activities follows:  
 
• Conduct of internal audits  
• Ongoing review of all reportable adverse events and all serious/unanticipated adverse events  
• Supervises internal DSM boards and/or performs as an internal DSMB  
• Has the authority to close and/or suspend trials for safety or trial conduct issues and may submit recommendations for corrective actions to the Associate Directors Executive Committee  
• Performs routine internal monitoring of both investigator -initiated and cooperative group cl inical 
trials  
 Data regarding number of subjects, significant toxicities, dose modifications, and responses will be discussed at regularly scheduled disease- oriented working group meetings.  The 
discussion will be documented in the minutes and summaries will be submitted to DSMC quarterly.  
 The Principal Investigator at the Coordinating Center is responsible for the overall conduct of the study at all of the participating institutions and for monitoring its progress.  The University of Colorado Cancer Center is the Coordinating 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 26 Center for this study and this site will coordinate patient 
enrollment.  There will be only one version of the protocol, and each participating institution will use that document.  The protocol must not be rewritten or modified by anyone other than the Principal Investigator at the Coordinating Center.  The Principal Investigator at the Coordinating Center is responsible for timely review of Adverse Events (AEs) to assure safety of the patients and for the review and timely submission of data for study analysis.   
 Each subject’s treatment outcomes will be monitored at least monthly by a conference call with the investigators and CRAs from all participating institutions. Data regarding the number of patients, significant toxicities, dos e modifications, and 
responses will be discussed and documented in meeting minutes.   
 The PI will provide a DSM report to the UCCC DSMC on a six month basis. DSM reports will contain data from all participating sites. The DSM report will include summaries  of 
minutes taken at monthly meetings, the participants’ demographic characteristics, expected versus actual recruitment rates, treatment retention rates, any quality assurance or regulatory issues (including a summary of any protocol deviations), summary of AEs and SAEs, summary of 
dose modifications, and any actions or changes with respect to the protocol. The DSM report to the DSMC will also include, if applicable, the results of any efficacy data analysis conducted. Results from these reviews will be pr ovided to all 
participating investigators to submit to their IRBs at the time of continuing review.  
 
5.11 Study Completion and Termination 
Study patients who have met any  of the following endpoint s will have 
completed the study:  
• SAE related to the study drug 
• Disease relapse  
• Death  
 
Study patients may be prematurely terminated from the study for the following reasons:  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 27 • Physician and/or patient decides to discontinue treatment for 
reasons other than an AE 
• ≥ Grade 3 related or possibly related non-hematologic  AE or 
grade 4 related or possibly related hematologic toxicity  that does 
not resolve or improve within 28 days  
• Noncompliance with the study protocol  
• Development of unrelated illness which compromises further participation in the study  
• The patient is lost to  follow up (no further data collection or 
submission will be expected)  
• The patient withdraws consent (no further data collection or submission will be expected)  
 
At termination, both concomitant medications and ongoing AEs are 
to be recorded, including any  new AEs reported at the end of the 
study.  Any unresolved AE at discontinuation of the study treatment 
should be followed until they have resolved or stabilized. Patients 
may choose to stop study treatment for any r eason without 
jeopardizing their relationship with healthcare providers . 
 
5.12 Study Activities and Assessments  
5.12.1  Schedule of Activities  
The time each assessment is performed relative to dosing is shown in the Schedule of Study Assessments (Section 2) .   
5.12.2  Screening Period 
Written consent must be obtained before performing any 
study -specific screening activities.  The screening activities 
outlined in the Schedule of Study Assessments (Section 2) must be completed within 28 days of starting study treatment , 
unless otherwise s pecified.  
 The investigators will be responsible for keeping a record of all subjects who sign an informed consent form for entry into 
the study. After the patient has signed and dated the informed 
consent form, all screening procedures have been completed and clinical eligibility has been confirmed, the patient can be officially enrolled in the study .   
5.12.3  Treatment Schedule  
Patients will receive study treatment as detailed in Section 5.1, and assessments will be performed as outlined in the 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 28 Schedule of Study Assessments (Section 2).  Patients will 
continue treatment in the absence of toxicity or disease 
progression.   
5.12.4  Follow Up 
Patients will be followed for 30 days after their final drug 
administration for AEs and SAEs.  Safety data beyond 30 
days may be reported if deemed relevant by the investigator.   
 Annual phone calls to appropriate patients will be made and documented f or five years after completion or discontinuation 
of the study.  
 Study can be terminated prior to the completion of five years,  
per Investigator discretion.   Patients still in follow -up will be 
contacted by study team if study is terminated prematurely.  
 
5.12.5  Study Assessments  
5.12.5.1  Vital Signs and ECOG Performance Status  
All vital signs (blood pressure, pulse, respiratory rate, temperature, oxygen saturation) and ECOG performance 
status grade ( See Appendix A) will be measured during  
screening and during study visits as specified in the Schedule of Study Assessments ( See Section 2).   
 
5.12.5.2  Physical Examination  
A complete physical examination, including measurement of  
height  during the first visit  and weight  at each visit , must be 
performed during  screening ( 28 days before beginning study 
treatment) and during study visits as specified in the Schedule of Study Assessments (Section 2).   
 
5.12.5.3  Adverse Events  
All AEs will be recorded from the first dose until 30 days after 
the last dose of study treatment.  Patients who experience a non-serious AE considered to be possibly or definitely related 
to study treatment will be followed until all significant changes have stabilized or returned to baseline, the patient withdraws 
consent, or death.  All SAEs  will be followed as described, 
regardless of their relationship to study treatment.  Safety data 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 29 beyond 30 days may be reported if it is deemed relevant by 
the investigator s. 
 
5.12.5.4  Laboratory Assessments 
The following laboratory assessments will be performed at 
screening and at study visits throughout the course of the 
patient’s participation in the trial.  See the Schedule of Study Assessments (Section 2) for specific timing.  
• Hematology: Hemoglobin, hematocrit, red blood cell 
count, total white blood cell count with differential, platelet 
count  
• Chemistries: A lbumin, alkaline phosphatase , ALT, AST, 
bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, potassium, sodium, total bilirubin , total 
protein  
• Coagulation: Prothrombin time, activated partial thromboplastin time  
• Pregnancy test (if applicable, 72 hours prior to the first dose of PF-0444913 ) 
 
5.12.5.5  EKGs  and QTc Calculation  
A 12-lead E KG will be performed during screening , 1-4 hours 
after the first dose of cycle 1, 1-4 hours after dosing on cycle 
1, day 15, 1-4 hours after the first dose of cycle 2 and 2- 5 days 
after the addition of any new azole antifungal medications . 
The QT interval will be calculated and corrected for heart rate 
(QTc) by Fridericia’s formula  if QTc is greater than 470 msec.  
(QTcF) is defined as: QTc(F) = QT/ (RR)0.33 . The QTcF 
duration will be used to make all decisions based on QT criteria.  If abnormal, triplicate E KGs should be performed and 
the average value used. Please refer to Section 5.10.2.2: Dose Delays and De- Escalation for guidance on dose 
adjustments required by prolonged QTcF intervals.  
 If a moderate/strong CYP3A4/5 inhibitor or TdP drug will be initiated in addition to  PF-04449913 the following guidance 
must be followed:  
• Prior to the start of a moderate/strong CYP3A4/5 inhibitor or TdP drug:  
o EKGs pre - PF-04449913 dose, 1 and 4 hours 
post- PF-04449913 dose  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 30 o Follow dose modifications for QTcF 
prolongation (Section 5.10.2.2)  
• After starting a moderate/strong C YP3A4/5 inhibitor or 
TdP drug:  
o EKGs on D ay 2 or 3 and on Day 5, 6, or 7  
o EK Gs pre - PF-04449913 dose, 1 and 4 hours 
post- PF-04449913 dose  
o Follow dose modifications for QTcF prolongation ( Section 5.10.2.2).  
• Perform additional EKG testing as appropriate.  
• Perform routine electrolyte monitoring (Ca, K, Cl, Mg), implement timely  electrolyte correction, followed by 
appropriate re- checking of values.  
• When there is an urgent need to start a moderate/strong CYP3A4/5 inhibitor or  TdP drug, 
administration of these medi cations should not be 
delayed; t he Investigator should consider temporarily 
interrupting PF -04449913 dosing, and  should 
implement these additional monitoring procedures as soon as it is  reasonably possible.  
 
5.12.5.6  Minimal Residual Disease (MRD)  
MRD assessmen ts using multiparameter flow cytometry will 
be performed on all bone marrow biopsy samples .  
 
5.12.5.7  Disease Assessments and Response Criteria  
Disease assessments will be performed on a routine basis according to standard of care practices.  This involves blood 
tests, and when indicated, bone marrow biopsies.  
 
Relapse definition  will be based on the LeukemiaNet 
guidelines :
35 >5% blasts in the bone marrow, reappearance of 
blasts in the peripheral blood or development of extramedullary disease.  
 
5.12.5.8  Correlative Assessments 
Tissue will be banked for future testing  and correlative 
studies. Each participating institution will employ their own IRB-approved tissue banking protocol for this purpose.  
  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 31 5.13 Definitions and Reporting Procedures for Adverse Events 
Subjects will be evaluated for AEs at each visit with the NCI -CTCAE 
version 4.0 3 used as a guide for the grading of severity.  All adverse 
clinical experiences, whether observed by the investigators  or 
reported by the patient, must be recorded, with details about the 
duration and intensity of each episode, the action taken with respect 
to the study, and the patients ’ outcome s.  The investigator s will 
evaluate each AE for its severity and its relationship to the study. The 
investigator s will appraise all abnormal laboratory results for their 
clinical significance .  If any abnormal laboratory result is  considered 
clinically significant, the investigator s will provide details about the 
action taken with respect to the study and the patients ’ outcome s. 
 
5.13.1  Definitions  of Adverse Events 
5.13.1.1  Adverse Event  
According to the International Conference on Harmonization  
of Technical Requirements for Registration of Pharmaceuticals for Human Use ( ICH) G uidelines (Federal 
Register. 1997;62(90):25691- 25709), Title 21 of the US Code 
of Federal Regulation ( CFR) 312.32, and Investigational New 
Drug (IND) Safety Reports, an AE is defined as follows:  
 
“Any untoward medical occurrence in a subject or clinical 
investigational subject administered a pharmaceutical product and which does not necessarily have a causal relationship  
with this treatment.  An AE can there fore be any untoward 
medical occurrence regardless of relationship to the medici nal 
(investigational) product.”  
 
Abnormal laboratory values for laboratory parameters specified in the study should not be recorded as an AE unless 
an intervention is required (repeat testing to confirm the 
abnormality is not considered an intervention) , the laboratory 
abnormality results in a SAE, or the AE results  in study 
termination or interruption/discontinuation of study treatment.  Medical conditions present at screening ( i.e.: before the study 
treatm ent is administered) are not SAE s and will not be 
recorded on SAE pages of the case report forms.  These medical conditions will be adequately documented in the 
patient chart.  However, medical conditions present at baseline that worsen in intensity or frequency during the 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 32 treatment or post -treatment periods will be reported and 
recorded as AEs. 
 
5.13.1.2  Serious Adverse Event  (SAE)  
An AE will be classified as an SAE if it meets one of the 
following criteria  (Reporting see section 5.13.4 and Appendix 
B): 
 
Fatal:  AE resulted in death.  
Life threatening:  The AEs placed the patient at immediate risk of death. 
This classification does  not apply to an AE that 
hypothetically might cause death if it were more severe.  
Hospitalization:  AE that  required or prolonged inpatient hospitalization. 
Hospitalizations for elective medical or surgical 
procedures or treatments planned before enrollment in 
the treatment plan or routine check -ups are not SAEs  by 
this criterion. Admission to a palliative unit or  hospice 
care facility is not considered to be a hospitalization.  
Disabling/incapacitating : AE r esulted in substantial and permanent disruption of 
the patient’s ability to carry out normal life functions.  
Congenital anomaly or 
birth defect:  An adverse ou tcome in a child or fetus of a patient 
exposed to the treatment regimen before conception or 
during pregnancy.  
Medically significant: The AE did not meet any of the above criteria, but could 
have jeopardized the patient and might have required 
medical or surgical intervention to prevent one of the 
outcomes listed above.  
5.13.1.3  Pregnancies  
Pregnancies and suspected pregnancies (including a positive 
pregnancy test regardless of age or disease state) of a female 
subject occurring while the subject is on PF-04449913, or 
within 28 days of the subject’s last dose of, are considered 
immediately reportable events. PF-04449913 is to be 
discontinued immediately, and the patient will discontinue the study.  
 For investigational products and for marketed products, an exposure during pregnancy (also referred to as exposure in-utero) occurs if:  
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 33 • A female becomes, or is found to be, pregnant either 
while receiving or  being exposed ( e.g., due to 
treatment or environmental exposure) or after discontinuing or having been directly exposed to the investigational product  
 
• A male has been exposed ( egg, due to treatment or 
environmental exposure) to the investigational produc t 
prior to or around the time of conception or is exposed during his partner’s pregnancy.  
 
If the outcome of the pregnancy meets the criteria for an SAE (i.e., ectopic pregnancy, spontaneous abortion, intrauterine 
fetal demise, neonatal death, or congenital anomaly [in a live born, a terminated fetus, an intrauterine fetal demise or a neonatal death]), the investigator should follow the procedures for reporting SAEs.  
 All neonatal deaths that occur within 28 days of birth should be reported, without regard to causality, as SAEs. In addition, any infant death after 28 days that the Investigator suspects is related to the in utero exposure to PF-04449913 should also 
be reported.  
 
5.13.2  Relationship of the Adverse Event to Treatment  
The investigator will eva luate the relationship of each AE to 
study treatment using the following criteria:  
Fatal:  AE resulted in death.  
Unrelated:  Another cause of the AE is more plausible, a temporal sequence 
cannot be established with the onset of the AE and 
administration of the treatment , or a causal relationship is 
considered biologically implausible.  
Possibly Related:  There is a clinically plausible time sequence between onset of the AE and administration of treatment, but the AE could also 
be attributed to concurrent or underlying disease, or the use of 
other drugs or procedures. Possibly related should be used 
when treatment is one of several biologically plausible AE 
causes.  
Definitely Related:  The AE is clearly related to use  of the treatment.  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 34  
5.13.3  Procedures for Recording Adverse Events  
5.13.3.1  Information to be Collected  
Whether considered related or not, during the reporting 
period, all SAE s and non- serious AEs are to be recorded on 
an AE case  report form ( CRF).  Patients who terminate the 
study early will be followed for 30 days after the last dose of study treatment for AEs and SAEs .  Patients who experience 
a non- serious AE considered to be possibly or definitely 
related to study treatment will be followed un til all significant 
changes have returned to baseline or stabilized, the patient dies, or the patient withdraws consent.  All SAE s will be 
followed as described, regardless of their relationship to study 
treatment.  During  the reporting period, the followi ng 
information should be collected:  
• Description of the AE, including onset and resolution dates  
• Relationship to treatment plan, treatment or other causality  
• Action taken, including use of concomitant medications  
• If the event is serious, note all criteria that apply  
 
5.13.3.2  Recording Serious Adverse Events 
• For SAEs, the primary event will be recorded on both an 
AE CRF and an SAE/Product Complaint Form; events 
occurring as a result of the SAE will be described on the 
SAE/Product Complaint Form in the narrative desc ription 
of the case 
• Death is an outcome of an event. The event that resulted in the death will be recorded and reported on both an 
SAE/Product Complaint Form and on an AE CRF.  
• For hospitalizations  or surgical or diagnostic procedures, 
the illness leading to the hospitalization or surgical or diagnostic procedure will be recorded as the SAE, not the 
procedure itself. The procedure will be captured in the 
narrative as part of the action taken in resp onse to the 
illness.  
5.13.4  Investigator Reporting Responsibilities   
The conduct of the study will comply with all Food and Drug 
Administration ( FDA) safety reporting requirements.   
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 35 5.13.4.1  Investigational New Drug Annual Reports  
If the FDA determines an IND is necessary, it is a requirement 
of 21 CFR 312.33 that an annual report be provided to the FDA within 60 days of the IND  anniversary date.   21 C FR 
312.33 provides the data elements  that are to be submitted in 
the report.    
 
5.13.4.2  Format for Adverse Event Reporting  
All AE reports will include the patient ’s number, age, sex, 
weight, severity of reaction (mild, moderate, severe), relationship to the study  (fatal relationship, definitely related, 
possibly related, unrelated), date and time of administration of test medications and all concomitant medications, and subsequent medical treatment provided. An investigator -
initiated research adverse event form will be utilized for reporting.  
 
5.13.4.3  Reporting to the IRB  
The Investigators will notify the IRB  of an AE or SAE 
according to institutional policy.   
 The serious adverse event report s will be  reviewed by PI. If 
the adverse event meets the coordinating center’s  criteria for 
reporting then an official signed report will be  submitted to the 
coordinating center’s  IRB. 
 
5.13.4.4  Reporting to Pfizer  
Within 24 hours of first awareness of the event (immediately if the event is fatal or life- threatening), the PI will report to 
Pfizer any SAE that occurs within the SAE reporting peri od 
(see Section 5.13.4.6 and Appendix B ).  
 
5.13.4.5  Non-serious  Adverse Event Reporting  
All non -serious AEs that occur before study drug 
administration but after informed consent is obtained and are associated with protocol -specific procedures (eg:  AEs 
associated with blood draws performed only for protocol 
purposes) will be reported according to local and coordinating 
center IRB guidlines .  
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 36 Events that occur before informed consent is obtained should 
be documented as medical history.   All non -serious AEs that 
occur between the first study treatment and the safety follow -
up 
 visit will be reported  according to local and coordinating 
center IRB guidlines .   
 All non -serious AEs that occur subsequent to the safety 
follow -up visit and are considered to be per tinent  in the 
opinion of the investigators may be reported according to local 
and coordinating center IRB guidlines . 
 
5.13.4.6  SAE Reporting 
SAEs will be reported within 24 hours of first awareness of the event (immediately if the event is fatal or life -threatening ). 
 All sites will report SAEs directly to Pfizer Drug Safety and Surveillance.  A copy of each SAE will also be sent to the U niversity of Colorado (coordinating center ) via email 
within 24 hours of the event.  
 The PI will then review and submit to the Uni versity of 
Colorado regulatory authorities and the FDA, if applicable, in accordance with 21 CFR 312.32.  All SAEs will be reported using the FDA 3500A Mandatory MedWatch report form. SAE form can be found at :  
 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsFo
rms/Forms/UCM048334.pdf  
 Periods:  
• All SAEs  that occur after informed consent is obtained 
will be reported up t o 30 days after administration of 
the last study treatment, regardless of relationship to study treatment .  
 
• All SAEs  that occur beyond 30 days after the 
administration of the last study treatment and are considered pertinent, in the opinion of the investigator s, may be reported. 
 
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 37 5.14 Statistical Methods and Sample Size Determination 
The one -year probability of relapse- free survival for  high-risk patients 
is roughly 30%.12,36-38 Using this as a null hypothesis, and 
speculating that the use of PF -04449913 will increase the one- year 
probability of relapse- free survival t o 50%, we will require 50 patients 
to allow for a 90% power to detect this 20% difference, with a 
significance level of 0.05.39 We predict the need to screen roughly 60 
patients to enroll 50 with high risk of relapse.   
 
Kaplan- Meier estimates using SAS software will be utilized for 
statistical analysis.  
 
5.15 Protocol Deviations  
Data from patient s who do not receive at least one full cycle of 
treatment due to early termination, death or non- compliance will be 
described.  Prot ocol violations during treatment and follow -up will be 
listed.  Addition al analyses will include summaries of patient 
demographics, baseline characteristics, complia nce and concurrent 
treatments.  When an emergency occurs that requires a deviation from the  protocol, a deviation will be made only for that subject.  A 
decision will be made as soon as possible to determine whether or not the subject for whom deviation from the protocol occurred is to continue on the study.  The subject’s medical records will c ompletely 
describe the deviation from the protocol and state the reasons for such deviation.  In addition, the i nvestigator s will notify the IRB , per 
IRB guidelines, in writing of such deviation from protocol. Non-
emergency minor deviations from the protocol will be permitted with approval of the  investigator s.  
 
6 ADMINISTRATIVE REQUIREMENTS 
6.1 Data and Safety Monitoring Plan 
Please refer to section 5.10.3: Data and Safety Monitoring. 
6.2 Ethics 
6.2.1  Institutional Review Board 
The protocol for this study has been designed in accordance 
with the general ethical principles outlined in the Declaration 
of Helsinki.  The review of this protocol by the IRB and the performance of all aspects of the study, including the methods 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 38 used for obtaining informed consent , are in accordance with 
principles enunciated in the Declaration, as well as ICH 
Guidelines, Title  21 of the CFR, Part 50 (Protection of Human 
Subjects ) and Part 56 (Institutional Review Boards ).  The 
investigator s will be responsible for preparing documents for 
submission to the IRB and obtaining written approval for this 
study.  The approval will be obtained prior to the initiation of 
the study.   The approval for both the protocol and informed 
consent must specify the date of approval, protocol number and version,  or amendment number.  Any amendments to the 
protocol after receipt of IRB approval must be submitted by 
the investigator s to the IRB for approval.  The i nvestigator s 
are also responsible for notifying the IRB  of any serious 
deviations from the protocol, or anything else that may involve added risk to subjects.  Any advertisements used to recruit subjects for the study must be reviewed and approved by the IRB prior to use.  The IRB will be informed regarding the 
progress of the study and any changes made to the protocol, 
and will be updated at least once a year.   For collabor ating 
institutions, consents will  be reviewed and approved by the 
local IRB.  
 
6.2.2  Patient Information and Consent  
The i nvestigator s must obtain informed consent of a subject 
or his/her designee prior to any study -related procedures as 
set forth in the CFR and ICH G uidelines  for Good Clinical 
Practice .  Documentation that informed consent occurred 
prior to the subject’s entry into the study and the informed consent process should be recorded in the subject’s source documents.  The original consent form signed and dated by the subject and by the person consenting the subject prior to the subject’s entry into the study must be maintained in the 
investigators’  study files.  No s ubstantial deviations from the 
informed consent form will be made.  The informed c onsent 
form will be submitted to and approved by the IRB prior to distribution to patients.  Before initiating protocol -specific 
procedures that would not otherwise be done, written and signed informed consent must be obtained.  This form must be signed and dated by the patient or by the patient’s legally 
authorized representative if the patient is unable to sign.  The case history for each patient will document that informed consent was obtained before the patient’s participation.  A copy of the informed consent must be provided to the patient 
or the patient’s legally authorized representative, and if 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 39 applicable, it will be provided in a certified translation into a 
foreign language.   Signed informed consents will remain in 
each patient’s chart and will be available for verification at any 
time.  
6.3 Record of Administration  
Accurate records will be kept in the source documents of all drug administration, including prescribing and dosing.   The i nvestigator s 
must ensure that the records and documents pertaining to the conduct of the study and the distribution of the protocol therapy (includes copies of CRF's and source documents such as: hospital records; clinical and office charts; laboratory notes; memoranda; subjects’ diaries or evaluation checklists; SAE reports; pharmacy dispensing records; recorded data from automated instruments; copies or transcriptions certified after verification as being accurate copies; microfiches, photographic negatives, microfil m, or magnetic 
media; x -rays; subject files; records kept at the pharmacy, at the 
laboratories, and at medico- technical departments involved in the 
clinical study; documents regarding subject treatment and drug accountability; original signed informed consents) be retained for as long as needed to comply with national and international regulations.  By signing the protocol, the investigator s agree to adhere to the 
documen t/records retention procedures . CRFs for this study will be 
collected at standard intervals by the local PI or the study coordinator  
and transferred to the coordinating center.   The local principal 
investigator will ensure that data collected for this study conform to all established guidelines for coding, collection, key entry and verificat ion.
   
6.4 Confidentiality 
The patient’s medical information obtained in this study is confidential, and disclosure to third parties is prohibited, unless the patient allows information to be shared with his or her personal physician or other appropriate medic al personnel  responsible for his 
or her welfare.  In compliance with United States federal reg ulations , 
data generated by this study will be available for inspection upon 
request by representatives of Pfizer , the  FDA, national and local 
health authoriti es, and the IRB, who may review and/or copy relevant 
medical records in accordance with the law.  Should direct access to medical records require a waiver or authorization separate from the subject’s statement of informed consent, it is the responsibility of the 
investigator s to obtain such permission in writing from the 
appropriate individual.  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 40 6.5 Study Auditing  
Investigator responsibilities are set out in the ICH guideline for Good 
Clinical Practice and in the US CFR.  Investigators must enter study 
data onto CR F’s or another data collection system.  The investigators 
will permit study -related audits by Pfizer  or its representatives, IRB 
review, and regulatory inspec tion(s) (e.g., FDA, EMEA, TPP), 
providing direct access to the facilities where the study took pl ace, to 
source documents, to CRF's, and to all other study documents.  The 
investigator s, or a designated member of the investigator s’ staff, 
must be available at some time during audits to review data, resolve 
any queries and to allow direct access to the subject s’ records (e.g., 
medical records, office charts, hospital charts, and study -related 
charts) for source data verification.  In addition, the Data Safety 
Monitoring Committee at the University of Colorado will audit the 
study according to institutional policy . 
   
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 41 7 REFERENCES  
 
1. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by 
multidimensional flow cytometry signifies high relapse risk in patients with de novo 
acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012.  
2. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic 
syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol 2010;21 Suppl 5:v158- 61. 
3. Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell 
transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol 2012.  
4. van den Brink MR, Porter DL, Giralt S, et al. Relapse after allogeneic 
hematopoietic cell therapy. Biol Blood Marrow Transplant 2010;16:S138- 45. 
5. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and 
donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem -cell transplantation. J Clin Oncol 2002;20:405- 12. 
6. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow 
transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001;19:3675- 84. 
7. Pollyea DA, Artz AS, Stock W, et al . Outcomes of patients with AML and 
MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007;40:1027- 32. 
8. Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an 
effecti ve method to predict relapse for ALL patients after allogeneic hematopoietic 
stem cell transplantation. Ann Hematol 2012;91:183- 92. 
9. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal 
residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29:1190- 7. 
10. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis 
as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394- 403. 
11. Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kroger N. 
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008;42:145 -57. 
12. Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities 
at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem -cell 
transplantation. J Clin Oncol 2011;29:2507- 13. 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 42 13. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic 
hematopoietic cell transplantation in patients with acute myeloid leukemia. J  Clin 
Oncol 2010;28:2859- 67. 
14. Unpublished data from the Fred Hutchinson Cancer Research Center.  
15. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 
2008;22:2454- 72. 
16. Heretsch P, Tzagkaroulaki L, Giannis A. Modulators of the hedg ehog 
signaling pathway. Bioorg Med Chem 2010;18:6613- 24. 
17. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat 
Rev Drug Discov 2006;5:1026- 33. 
18. Hahn H, Christiansen J, Wicking C, et al. A mammalian patched homolog 
is expressed in target tissues of sonic hedgehog and maps to a region associated 
with developmental abnormalities. J Biol Chem 1996;271:12125- 8. 
19. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth 
inhibition by hedgehog pathway blockade. Science 2002;297:1559- 61. 
20. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates 
medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513- 6. 
21. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed 
in medulloblastomas  from mice with heterozygous germ -line mutation of patched. 
Cancer Res 2000;60:2239- 46. 
22. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway 
using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/ -)p53( -/-) 
mice. Cancer  Cell 2004;6:229- 40. 
23. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for 
hedgehog signalling in cancer. Nature 2008;455:406- 10. 
24. Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling 
pathway in malignant hematological neoplasms. Am J Pathol 2012;180:2- 11. 
25. Kobune M, Takimoto R, Murase K, et al. Drug resistance is dramatically 
restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009;100:948- 55. 
26. Bai LY, Chiu CF, Lin CW, et al. Differential expression of Sonic hedgehog 
and Gli1 in hematological malignancies. Leukemia 2008;22:226- 8. 
27. Queiroz KC, Ruela- de-Sousa RR, Fuhler GM, et al. Hedgehog signaling 
maintains chemoresistance in myeloid leukemic cells. Oncogene 2010;29:6314-22. 
28. Lin TL, Wang QH, Brown P, et al. Self -renewal of acute lymphocytic 
leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI -
926. PLoS One 2010;5:e15262.  
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 43 29. Kawahara T, Kawaguchi -Ihara N, Okuhashi Y, Itoh M, Nara N, Tohda S. 
Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. 
Anticancer Res 2009;29:4629- 32. 
30. Ji Z, Mei FC, Johnson BH, Thompson EB, Cheng X. Protein kinase A, not 
Epac, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J Biol Chem 2007;282:37370- 7. 
31. Shih AY, Schairer A, Barrett CL. Cycling toward leukemia stem cell 
elimination with a selective sonic hedgehog antagonist. Blood. 2011: ASH Abstract #3776.  
32. Jamieson C, Cortes JE, Oehler V.  Phase 1 dose- escalation study of PF -
0444913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies.  Blood. 2011: ASH abstract #424.  
33. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in 
Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005- 9. 
34. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic 
scoring system for myelodysplastic syndromes. Blood 2012;120:2454- 65. 
35. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute 
myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453- 74. 
36. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of 
postrem ission therapy for residual disease- positive patients with acute myeloid 
leukemia. J Clin Oncol 2008;26:4944- 51. 
37. Stelljes M, Beelen DW, Braess J, et al. Allogeneic transplantation as post -
remission therapy for cytogenetically high- risk acute myeloid leukemia: landmark 
analysis from a single prospective multicenter trial. Haematologica 2011;96:972-9. 
38. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative Analysis of 
the Value of Allogeneic Hematopoietic Stem -Cell Transplantation in Acute Myeloid  
Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories. J Clin Oncol 2012.  
39. Simon R. Optimal two -stage designs for phase II clinical trials. Control Clin 
Trials 1989;10:1- 10. 
 
8 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 44  APPENDIX A  - ECOG Performance Status Scale  
 
SCORE  DESCRIPTION  
0 Fully active, able to carry on all pre- disease 
performance without restriction.  
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work.  
2 Ambulatory and capable of all self -care but unable to 
carry out any work activities.  Up and about more than 
50% of waking hours.  
3 Capable of only limited self -care, confined to bed or 
chair more than 50% of waking hours.  
4 Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5 Dead  
 
 
 Confidential    
   
      
 
COMIRB #12- 1558 - Version #7 : 15 OCT 201 9 45 9 APPENDIX B  - Pfizer Safety Reporting Policy  
Pfizer Serious Adverse Event Reporting Policy 
For Investigator -Initiated Research Studies  
Reporting of Serious Adverse Events. Within 24 hours of first awareness of the event (immediately 
if the event is fatal or life- threatening), Principal Investigator will report to Pfizer by facsimile any 
Serious Adverse Event (“SAE,” as defined below) that  occurs during the SAE reporting period (as 
defined below) in a Study subject assigned to receive the Pfizer product that is the focus of the 
Study (“Pfizer Product”). Principal Investigator will report such SAEs using an FDA MEDWATCH form, CIOMS form, Inv estigator -Initiated Research Serious Adverse Event (IIR 
SAE) form, or other Pfizer agreed upon form for SAE reporting. The Reportable Event Fax Cover 
Sheet provided by Pfizer should also be included. Principal Investigator should report SAEs as soon 
as they are determined to meet the definition, even if complete information is not yet available.  
a. SAE Definition. An SAE is any adverse event, without regard to causality, that is life -threatening 
or that results in any of the following outcomes: death; in- patient hospitalization or prolongation 
of existing hospitalization; persistent or significant disability or incapacity; or a congenital anomaly or birth def ect. Any other medical event that, in the medical judgment of the Principal Investigator, 
may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed above is also considered an SAE. A planned medical or  surgical procedure is not, 
in itself, an SAE.  
b. Exposure During Pregnancy, Exposure During Lactation, and Lack Of Effect. Even though there 
may not be an associated SAE, exposure to the Pfizer Product during pregnancy and exposure to 
the Pfizer Product during lactation are reportable, and lack of effect of the Pfizer Product may also 
be reportable. This requirement is further explained in the training material provided by Pfizer (see Section f, below). In this Agreement, the term SAE will be understood t o include exposure during 
pregnancy, exposure during lactation, and reportable instances of lack of effect.  
c. SAE Reporting Period. The SAEs that are subject to this reporting provision are those that occur 
from after the first dose of the Pfizer Product  through 28 calendar days after the last administration 
of the Pfizer Product or longer if so specified in the Protocol. In addition, investigators should 
submit SAEs to Pfizer any time after the administration of the last dose of the Pfizer Product, if th e 
Principal Investigator suspects a causal relationship between the Pfizer Product and the SAE.  
d. Follow -Up Information. Institution will assist Pfizer in investigating any SAE and will provide 
any follow-up information reasonably requested by Pfizer.  
e. Regulatory Reporting. Reporting an SAE to Pfizer does not relieve Institution of responsibility 
for reporting it to FDA and/or other appropriate Regulatory Authorities, as required.   
f. Pfizer -Provided Training. Pfizer will make available training material that provides information 
about the SAE reporting requirements for IIR studies. Principal Investigator will review this 
material and share it with any Study staff engaged in the reporting of SAEs.”
 